Damir Vrbanec

2.1k total citations
45 papers, 486 citations indexed

About

Damir Vrbanec is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Damir Vrbanec has authored 45 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 12 papers in Cancer Research and 10 papers in Molecular Biology. Recurrent topics in Damir Vrbanec's work include HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (5 papers). Damir Vrbanec is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (5 papers). Damir Vrbanec collaborates with scholars based in Croatia, Austria and Romania. Damir Vrbanec's co-authors include Jasminka Jakić‐Razumović, Branka Petričević, Maja Sirotković-Skerlev, Zsuzsanna Kahán, Jasminka Pavelić, Jelena Knežević, Jozef Mardiak, Godfrey E. Etokebe, Zlatko Dembić and J. Eglītis and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Damir Vrbanec

44 papers receiving 469 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Damir Vrbanec Croatia 14 269 129 127 91 69 45 486
Claudio Flores Peru 11 278 1.0× 85 0.7× 85 0.7× 101 1.1× 136 2.0× 41 493
Whitney A. Spannuth Graybill United States 13 221 0.8× 154 1.2× 60 0.5× 60 0.7× 54 0.8× 40 549
Diana P. English United States 14 275 1.0× 183 1.4× 85 0.7× 53 0.6× 112 1.6× 31 676
Kosuke Ichikawa Japan 9 308 1.1× 181 1.4× 86 0.7× 72 0.8× 173 2.5× 19 542
Zaida Morante Peru 11 266 1.0× 149 1.2× 142 1.1× 113 1.2× 140 2.0× 38 479
Lauren Baldwin United States 10 149 0.6× 157 1.2× 102 0.8× 55 0.6× 46 0.7× 40 572
Connie G. Chiu Canada 14 304 1.1× 203 1.6× 84 0.7× 104 1.1× 103 1.5× 19 702
Vivek Khemka United States 8 371 1.4× 71 0.6× 142 1.1× 120 1.3× 104 1.5× 23 519
Chara Stavraka United Kingdom 16 322 1.2× 229 1.8× 106 0.8× 128 1.4× 118 1.7× 45 755
Ainhoa Madariaga Spain 11 415 1.5× 227 1.8× 90 0.7× 88 1.0× 80 1.2× 51 703

Countries citing papers authored by Damir Vrbanec

Since Specialization
Citations

This map shows the geographic impact of Damir Vrbanec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damir Vrbanec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damir Vrbanec more than expected).

Fields of papers citing papers by Damir Vrbanec

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Damir Vrbanec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damir Vrbanec. The network helps show where Damir Vrbanec may publish in the future.

Co-authorship network of co-authors of Damir Vrbanec

This figure shows the co-authorship network connecting the top 25 collaborators of Damir Vrbanec. A scholar is included among the top collaborators of Damir Vrbanec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Damir Vrbanec. Damir Vrbanec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Popović, Marina, et al.. (2023). Interleukin 17 in early invasive breast cancer. Frontiers in Oncology. 13. 1171254–1171254. 8 indexed citations
2.
Šeparović, Robert, et al.. (2021). Immunity and cancer: role of tumor-infiltrating lymphocytes in triple-negative breast cancer. SHILAP Revista de lepidopterología. 49(1). 20–28.
3.
Kurbel, Sven, et al.. (2021). The process of urinary bladder cancer recurrence in 33 patients with 113 tumors, analyzed by changes in IHC features of 80 pairs of subsequent tumors.. Journal of Clinical Oncology. 39(15_suppl). e16507–e16507. 1 indexed citations
4.
Šeparović, Robert, et al.. (2020). Characteristics and Prognosis of Triple-Negative Breast Cancer Patients: a Croatian Single Institution Retrospective Cohort Study. SHILAP Revista de lepidopterología. 1 indexed citations
5.
Jakopović, Marko, et al.. (2018). [CANCER PATIENTS FOLLOW-UP – CROATIAN SOCIETY FOR MEDICAL ONCOLOGY CLINICAL GUIDELINES Part V: melanoma, sarcomas, central nerve system tumors, lung cancer].. PubMed. 139(1-2). 17–23. 2 indexed citations
6.
Šeparović, Robert, et al.. (2018). CANCER PATIENTS FOLLOW-UP – CROATIAN SOCIETY OF MEDICAL ONCOLOGY CLINICAL GUIDELINES Part I: breast cancer, uterine cancer, cervical cancer, ovarian cancer.. PubMed. 138(3-4). 167–72. 1 indexed citations
7.
8.
Balić, Marija, Rupert Bartsch, Thomas Bauernhofer, Damir Vrbanec, & Eduard Vrdoljak. (2017). Biosimilars in the Treatment of Breast Cancer. Breast Care. 12(3). 192–194. 1 indexed citations
9.
Čeović, Romana, Snježana Dotlić, Ivana Ilić, et al.. (2016). [CROATIAN SOCIETY FOR MEDICAL ONCOLOGY CLINICAL GUIDELINES FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP OF PATIENTS WITH MELANOMA].. PubMed. 138(1-2). 22–9. 2 indexed citations
10.
Zielinski, Christoph, István Láng, S. Beslija, et al.. (2015). Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer. 114(2). 163–170. 21 indexed citations
11.
Sirotković-Skerlev, Maja, et al.. (2014). Sirtuins in tumorigenesis. Periodicum Biologorum. 116(4). 381–386. 3 indexed citations
12.
13.
Rordorf, Tamara, Ibrahim A. Hassan, Hamdy A. Azim, et al.. (2014). Bone health in breast cancer patients: A comprehensive statement by CECOG/SAKK Intergroup. The Breast. 23(5). 511–525. 14 indexed citations
14.
Jakić‐Razumović, Jasminka, et al.. (2014). Prognostic Value of Ki-67 in Breast Carcinoma: Tissue Microarray Method Versus Whole Section Analysis- Potentials and Pitfalls. Pathology & Oncology Research. 21(2). 315–324. 2 indexed citations
15.
Kaczirek, Klaus, Tudor–Eliade Ciuleanu, Damir Vrbanec, et al.. (2014). FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. Clinical Colorectal Cancer. 14(2). 91–98. 20 indexed citations
16.
Jakić‐Razumović, Jasminka, et al.. (2013). Prognostic value of proliferation markers expression in breast cancer. Medical Oncology. 30(2). 523–523. 15 indexed citations
17.
Vrbanec, Damir, et al.. (2012). Role of HER2 signaling pathway in breast cancer: biology, detection and therapeutical implications. Periodicum Biologorum. 114(4). 505–510. 8 indexed citations
18.
Knežević, Jelena, Dinko Pavlinić, William Rose, et al.. (2012). Heterozygous Carriage of a Dysfunctional Toll-like Receptor 9 Allele Affects CpG Oligonucleotide Responses in B Cells. Journal of Biological Chemistry. 287(29). 24544–24553. 5 indexed citations
19.
Etokebe, Godfrey E., Jelena Knežević, Branka Petričević, et al.. (2009). Single-Nucleotide Polymorphisms in Genes Encoding Toll-Like Receptor -2, -3, -4, and -9 in Case–Control Study with Breast Cancer. Genetic Testing and Molecular Biomarkers. 13(6). 729–734. 45 indexed citations
20.
Petričević, Branka, Barbara Wessner, Monika Sachet, et al.. (2009). CL097, A TLR7/8 LIGAND, INHIBITS TLR-4-DEPENDENT ACTIVATION OF IRAK-M AND BCL-3 EXPRESSION. Shock. 32(5). 484–490. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claudio Flores Breakdown of academic impact, for papers by Whitney A. Spannuth Graybill Breakdown of academic impact, for papers by Diana P. English Breakdown of academic impact, for papers by Kosuke Ichikawa Breakdown of academic impact, for papers by Zaida Morante Breakdown of academic impact, for papers by Lauren Baldwin Breakdown of academic impact, for papers by Connie G. Chiu Breakdown of academic impact, for papers by Vivek Khemka Breakdown of academic impact, for papers by Chara Stavraka Breakdown of academic impact, for papers by Ainhoa Madariaga
Rankless by CCL
2026